DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Treatment of spinocerebellar ataxia with buspirone.

Author(s): Assadi M, Campellone JV, Janson CG, Veloski JJ, Schwartzman RJ, Leone P

Affiliation(s): Department of Medicine, Division of Neurology, Cooper University Hospital/Robert Wood Johnson Medical School, Camden, New Jersey, USA. Assadi-Mitra@cooperhealth.edu

Publication date & source: 2007-09-15, J Neurol Sci., 260(1-2):143-6. Epub 2007 May 23.

Publication type: Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Preliminary data suggest potential benefit of 5-HT receptor agonists in the treatment of ataxias. We studied the effects of buspirone in a cohort of twenty patients with spinocerebellar ataxia (SCA). Twenty patients were treated in this double-blind, placebo controlled, cross-over trial with either buspirone HCl 30 mg twice daily or placebo for 3 months. Buspirone was not shown to be superior to placebo in the treatment of patients with SCA.

Page last updated: 2008-01-02

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017